Atai reports its Q2 2022 results, announces a new $175 million loan facility and streamlines its operations.
Atai reports its Q2 2022 results, announces a new $175 million loan facility and streamlines its operations.
Mind Medicine announces a reverse share split of its common shares at a 1-15 ratio. Exchange symbols will remain the same but new CUSIP numbers will be assigned by the appropriate regulators.
Compass Pathways reports its Q2 2022 results. Preparing for its Phase 3 clinical trial for TRD. Net loss of $21.0 million. Cash (and equivalents) of $207.2 million.
Compass Pathways announces the launch of a Phase II clinical trial using psilocybin-based COMP360 as a treatment for anorexia nervosa.
Red Light Holland acquires two of the Netherlands premier shops for psychedelic truffles and wellness products.
Pasithea Therapeutics announces being awarded a research grant of AUD $1 million (US$694,000) for its psychedelics-based research for ALS disease.
Awakn Life Sciences announces UK government grant funding to cover 2/3rds of the costs of its Phase III clinical trial for alcohol use disorder (AUD).
Compass Pathways announces that Kabir Nath will replace George Goldsmith as CEO effective August 1, 2022.
Better Life Pharma announces additional funding to study BETR-001 as a treatment for depression, via the Mitacs Accelerate program.
Red Light Holland announces a partnership with platinum-selling rapper, Wiz Khalifa, to launch Red Light Holland's MISTERCAP brand of psilocybin-based products.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now